Zai Lab
ZLAB
25.31
-0.27
-1.06%
Zai Lab
US · ZLAB
#2554 by market cap
Listed 2017
25.31
-0.27
-1.06%
Live - 5344 symbols - heartbeat 412s ago
· 2026-10-08 07:28
Pre-market
24.50
-3.20%
After-hours
24.80
-2.02%
Overnight
24.55
-3.00%
- Market cap
- 2.84B
- P/E (TTM)i
- -14.89
- P/Bi
- 4.68
- EPSi
- -1.60
- Div yieldi
- 0.00%
- 52W posi
- 59%
Reader sentiment
Are you bullish or bearish on ZLAB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.97, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +15.33% YoY
Margins
- Gross margin
- 58.47%
- Operating margin
- -48.59%
- Net margin
- -38.15%
Key ratios & quality
- Altman Z-Scorei
- 0.97
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 129.00K | 12.99M | 48.96M | 144.31M | 215.04M | 266.72M | 398.99M | 460.16M |
| Gross profit | 86.00K | 9.24M | 32.22M | 92.07M | 141.02M | 170.90M | 251.13M | 269.08M |
| Selling & admin expenses | 21.58M | 70.21M | 111.31M | 218.83M | 258.97M | 281.61M | 298.74M | 277.61M |
| Research & development | 120.28M | 142.22M | 222.71M | 573.31M | 286.41M | 265.87M | 234.50M | 220.90M |
| Operating profit | -141.77M | -203.20M | -301.80M | -695.95M | -392.89M | -374.14M | -273.95M | -223.57M |
| Pretax profit | -138.49M | -194.32M | -267.79M | -703.41M | -443.07M | -334.62M | -257.10M | -178.46M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.93M |
| Net profit | -139.08M | -195.07M | -268.91M | -704.47M | -443.29M | -334.62M | -257.10M | -175.54M |
| Basic EPS | -3 | -3 | -4 | -8 | -5 | -4 | -3 | -2 |
| Diluted EPS | -2.64 | -3.03 | -3.50 | -7.60 | -4.60 | -3.50 | -2.60 | -1.60 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 106.49M | 109.98M | 116.10M | 127.60M | 99.61M | 106.31M |
| Gross profit | 67.84M | 66.76M | 69.21M | 65.27M | 61.28M | 58.15M |
| Selling & admin expenses | 63.42M | 71.04M | 70.11M | 73.04M | 65.07M | 72.87M |
| Research & development | 60.73M | 50.61M | 47.93M | 61.63M | 65.59M | 61.77M |
| Operating profit | -56.30M | -54.90M | -47.97M | -68.26M | -69.28M | -76.49M |
| Pretax profit | -48.44M | -40.73M | -35.96M | -53.34M | -49.58M | -51.85M |
| Tax | 0 | 0 | 0 | -2.93M | 1.44M | -1.02M |
| Net profit | -48.44M | -40.73M | -35.96M | -50.41M | -51.02M | -50.83M |
| Basic EPS | 0 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.40 | -0.40 | -0.30 | -0.50 | -0.50 | -0.50 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 269.15M | 292.46M | 1.22B | 1.50B | 1.12B | 939.61M | 1.05B | 1.02B |
| Cash & ST investments | 263.30M | 275.93M | 1.19B | 1.41B | 1.01B | 806.45M | 779.67M | 689.57M |
| Inventory | 4.00K | 6.01M | 13.14M | 18.95M | 31.62M | 44.83M | 39.88M | 74.75M |
| Total assets | 301.99M | 355.15M | 1.30B | 1.61B | 1.22B | 1.04B | 1.19B | 1.17B |
| Total current liabilities | 48.84M | 46.64M | 98.04M | 192.90M | 139.84M | 203.07M | 299.39M | 416.17M |
| Short-term debt | 3.64M | 10.80M | 5.21M | 5.93M | 7.05M | 7.10M | 139.76M | 210.87M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 50,906,000.00 | 60,493,000.00 | 128,293,000.00 | 230,000,000.00 | 174,545,000.00 | 240,177,000.00 | 344,855,000.00 | 456,884,000.00 |
| Total equity | 251.08M | 294.66M | 1.17B | 1.38B | 1.05B | 796.12M | 840.90M | 715.50M |
| Retained earnings | -249.63M | -444.70M | -713.60M | -1.42B | -1.86B | -2.20B | -2.45B | -2.63B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.04B | 1.03B | 1.03B | 1.02B | 944.73M | 914.04M |
| Cash & ST investments | 757.26M | 732.16M | 717.16M | 689.57M | 661.32M | 617.52M |
| Inventory | 53.05M | 61.70M | 67.14M | 74.75M | 85.96M | 90.89M |
| Total assets | 1.17B | 1.16B | 1.16B | 1.17B | 1.10B | 1.07B |
| Total current liabilities | 319.81M | 331.50M | 359.77M | 416.17M | 392.98M | 428.58M |
| Short-term debt | 179.98M | 180.09M | 208.52M | 210.87M | 219.80M | 243.13M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 362,577,000.00 | 372,366,000.00 | 398,995,000.00 | 456,884,000.00 | 433,756,000.00 | 467,756,000.00 |
| Total equity | 810.75M | 791.74M | 759.95M | 715.50M | 661.98M | 607.04M |
| Retained earnings | -2.50B | -2.54B | -2.58B | -2.63B | -2.68B | -2.73B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -97.54M | -191.01M | -216.06M | -549.23M | -367.64M | -198.18M | -214.87M | -150.79M |
| Depreciation & amortization | 1.65M | 3.77M | 4.64M | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| Free cash flow | -107.66M | -206.25M | -226.72M | -568.18M | -392.63M | -206.67M | -276.39M | -164.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 141.00M | 216.20M | 1.14B | 818.88M | 0 | 0 | 217.35M | 0 |
| Ending cash balance | 62.95M | 76.44M | 442.86M | 964.90M | 1.01B | 791.26M | 550.78M | 780.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -61.70M | -31.02M | -32.04M | -26.02M | -11.91M | -63.41M |
| Depreciation & amortization | 3.46M | 3.74M | 3.90M | 3.92M | 3.94M | 4.17M |
| Free cash flow | -65.57M | -35.20M | -36.13M | -27.32M | -34.20M | -64.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 858.38M | 833.38M | 818.27M | 780.69M | 752.43M | 708.64M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -57.20 | -71.49 | -36.74 | -55.27 | -36.55 | -36.34 | -31.41 | -22.56 |
| ROA %i | -50.42 | -59.37 | -32.54 | -48.46 | -31.33 | -29.66 | -23.14 | -14.89 |
| ROIC %i | -57.66 | -69.75 | -36.41 | -54.71 | -37.20 | -39.89 | -32.34 | -20.98 |
| 5-year avg ROE %i | -- | -- | -- | -55.11 | -51.45 | -47.28 | -39.26 | -36.43 |
| EBIT margin %i | -106,949.81 | -1,494.23 | -546.60 | -487.43 | -206.04 | -140.28 | -63.87 | -37.65 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.51 | 6.27 | 12.40 | 7.78 | 8.04 | 4.63 | 3.51 | 2.45 |
| Quick ratioi | 5.39 | 6.00 | 12.16 | 7.59 | 7.56 | 4.29 | 2.90 | 1.94 |
| Debt / assetsi | 1.21 | 6.13 | 1.43 | 0.97 | 1.67 | 1.46 | 12.94 | 19.13 |
| LT debt / equityi | -- | 3.73 | 1.15 | 0.70 | 1.28 | 1.01 | 1.63 | 1.87 |
| Interest coveragei | -3,489.83 | -662.20 | -1,478.48 | -- | -- | -- | -113.07 | -33.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 938.10 | 154.89 | 75.96 | 40.35 | 28.86 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -32.05 | -28.41 | -28.97 | -22.56 | -24.19 | -26.91 |
| ROA %i | -23.32 | -19.76 | -19.29 | -14.89 | -15.70 | -16.81 |
| ROIC %i | -31.15 | -27.55 | -26.73 | -20.98 | -21.42 | -22.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -59.46 | -48.72 | -45.75 | -37.65 | -38.37 | -41.09 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.26 | 3.12 | 2.87 | 2.45 | 2.40 | 2.13 |
| Quick ratioi | 2.64 | 2.51 | 2.29 | 1.94 | 1.84 | 1.61 |
| Debt / assetsi | 16.39 | 16.44 | 18.93 | 19.13 | 21.16 | 23.69 |
| LT debt / equityi | 1.52 | 1.43 | 1.43 | 1.87 | 1.83 | 1.89 |
| Interest coveragei | -74.74 | -50.86 | -42.52 | -33.26 | -30.74 | -30.87 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- ZEJULA is the largest reported line at 30.17% of revenue, across 10 reported segments.
- No single line clears half of revenue; VYVGART / VYVGART Hytrulo is next at 22.45%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
ZEJULA30.17%
VYVGART / VYVGART Hytrulo22.45%
NUZYRA16.08%
Optune11.48%
QINLOCK9.02%
XACDURO7.48%
AUGTYRO2.08%
Collaboration revenue0.53%
KarXT0.52%
Other0.18%
Quote time 2026-10-08 07:28:14 · For reference only, not investment advice and not tailored to your situation.